Skip to content
Home » Spectradyne attends Applied Pharmaceutical Nanotechnology 2019

Spectradyne attends Applied Pharmaceutical Nanotechnology 2019

January 13, 2020 – Spectradyne attends Applied Pharmaceutical Nanotechnology 2019

Spectradyne was pleased to sponsor (for the second year in a row) the one-day Applied Pharmaceutical Nanotechnology event held in late October at Pfizer in Cambridge, MA. This annual event, put on by the non-profit, The Boston Society, brings together experts from industry, academia and regulatory to discuss topical issues related to uses of nanotechnology in pharmaceuticals.

Spectradyne jointly presented a poster with Pfizer, entitled “Simulation of Label-Free PK Evaluation of Nanoparticles in Complex Media”. The poster detailed work done jointly between Spectradyne and Pfizer to look at the potential of using Spectradyne’s nCS1 as a way of quantifying nanoparticle drug products in a complex biological matrix such as plasma, enabling label-free PK evaluation. The poster can be downloaded here.

Greg Troiano, VP of Technology and Chief Engineer from Seer, Inc., once again gave the initial plenary talk, updating us on the progress of this company over the past year. Seer is bringing to market some very exciting technology to analyze the proteome “to enable novel insights and breakthroughs in the understanding of biology and disease.” They design multiple nanoparticles to sample the proteome, enabling close monitoring of the presence and progression of specific disease markers, which can be used to drive treatment decisions.

One of the speakers also gave a sneak peek at an announcement (officially made a month later) of a public/private consortium committing to build a new center for advanced biological innovation and manufacturing in the Metro Boston area. The center, slated to be completed in late 2021, will further cement the greater Boston’s leading position in cell and gene therapies, by providing production facilities to address the current shortage of raw materials necessary for research efforts. Currently, “Researchers have to wait up to 18 months for overburdened commercial manufacturers to produce engineered cells and viral vectors needed for their work, slowing the pace of knowledge development.”

Overall, this event was information rich, and provided an excellent forum for free discussion of many of the challenges facing people working in Applied Pharmaceutical Nanotechnology. Interesting and exciting new work was presented, showing that the future for these technologies is indeed bright!

Please continue to follow our blog as we share insights, technical details, and generally geek-out with you about nanoparticle science!

Email us for more information, or to discuss your particular application directly.